Josanna Rodriguez-Lopez, MD
Pulmonary Disease · New York, NYNPI 1780833459
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $107,714 of the $128,457 with a category attached, or 83.9%. 7 manufacturers reported payments, led by Merck at 39.1% of the total. Among pulmonary disease clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 220 payments — averaging $583.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$50K
- United Therapeutics Corporation$29K
- Bayer$24K
- Actelion Pharmaceuticals US, Inc.$19K
- Chiesi USA, Inc.$3K
- Janssen Scientific Affairs, LLC$3K
- plus $209 from 1 others
Across 47 payments — averaging $4506.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- United Therapeutics Corporation$88K
- Merck$64K
- Actelion Pharmaceuticals, Ltd$33K
- Bayer$27K
What the payments were for
- Consulting fees$107,71484%
- Travel & lodging$13,86811%
- Food & beverage$6,8235%
- Education$530%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 62 | $50,282 |
| United Therapeutics Corporation | 74 | $28,696 |
| Bayer | 43 | $23,667 |
| Actelion Pharmaceuticals US, Inc. | 36 | $19,447 |
| Chiesi USA, Inc. | 3 | $3,380 |
| Janssen Scientific Affairs, LLC | 1 | $2,778 |
| Inari Medical, Inc. | 1 | $209 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Adempas$21,309
- OPSUMIT$14,675
- UPTRAVI$10,794
- TYVASO$6,850
- WINREVAIR$4,674
- FLOWTRIEVER CATHETER, S$209
- CT THROMBECTOMY SYSTEM KIT$209
- REMODULIN$105
- ORENITRAM$105
How this compares
$128,457 in reported general payments places this provider in the 95th percentile of 1,115 pulmonary disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 94 | $2,345,278 |
| Tyvaso DpiTreprostinil | 95 | $2,204,790 |
| OpsumitMacitentan | 148 | $1,882,014 |
| AdempasRiociguat | 74 | $1,019,281 |
| Ambrisentan | 88 | $289,463 |
| WinrevairSotatercept-Csrk | 18 | $256,972 |
| Tadalafil | 144 | $220,384 |
| LetairisAmbrisentan | 11 | $144,885 |
| AdcircaTadalafil | 18 | $91,436 |
| Sildenafil Citrate | 336 | $82,173 |
| EliquisApixaban | 78 | $63,863 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 39 | $33,370 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 38 | $17,485 |
| JardianceEmpagliflozin | 18 | $14,540 |
| XareltoRivaroxaban | 21 | $13,831 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $19,447 | $4,227,291242 claims |
| BayerAdempas | $23,667 | $1,019,28174 claims |
| MerckWinrevair | $50,282 | $256,97218 claims |
| United Therapeutics CorporationAdcirca | $28,696 | $91,43618 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,115 pulmonary disease providers in New York.
Other pulmonary disease in New York
- Charles PowellNew York$654K
- Bisher AkilNew York$480K
- Sonali SethiNew York$388K
- Johnathan RaskinNew York$338K
- Monica KraftNew York$247K
- Jamie BessichNew York$226K
- Ronald CrystalNew York$213K
- Michael NiedermanNew York$176K
- Wilfredo TalaveraNew York$145K
- Kenneth BergerNew York$126K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.